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ABSTRACT
Objective BCG vaccination is frequently delayed in low- 
income countries. Restrictive vial- opening policies, where 
a vial of BCG vaccine is not opened for few children, are 
a major reason for delay. During delays, children are 
unprotected against tuberculosis (TB) and deprived of non- 
specific effects of BCG. We assessed the potential effect and 
cost- effectiveness of disregarding the restrictive vial- opening 
policy, on TB and all- cause mortality, in children aged 0–4 
years in Guinea- Bissau.
Methods Using static mathematical models, we estimated 
the absolute and percentage change in TB and all- cause 
deaths, in children aged 0–4 years, between the current 
BCG vaccine restrictive- opening policy scenario, and a 
non- restrictive policy scenario where all children were 
vaccinated in the first health- facility contact. Incremental 
cost- effectiveness was estimated by integration of vaccine 
and treatment costs.
Findings Disregarding the restrictive BCG vial- opening 
policy was estimated to reduce TB deaths by 11.0% (95% 
uncertainty range (UR):0.5%–28.8%), corresponding to 4 
(UR:0–15) TB deaths averted per birth cohort in Guinea- 
Bissau, resulting in incremental cost- effectiveness of US$ 
911 per discounted life- year gained (LYG) (UR:145–9142). 
For all- cause deaths, the estimated reduction was 8.1% (UR: 
3.3%–12.7%) corresponding to 392 (UR:158–624) fewer all- 
cause deaths and an incremental cost- effectiveness of US$ 9 
(UR:5–23) per discounted LYG.
Conclusions Disregarding the restrictive BCG vial- opening 
policy was associated with reductions in TB deaths and 
all- cause deaths and low cost- effectiveness ratios. Our 
results suggest that it would be cost- effective to disregard 
the restrictive vial- opening policy. Other settings with similar 
practice are also likely to gain from disregarding this policy.
INTRODUCTION
The BCG vaccine was developed to protect 
against tuberculosis (TB), and is currently the 
only approved TB vaccine.1 The efficacy and 
effectiveness of BCG against TB varies consider-
ably between studies and populations,2 however, 
neonatal BCG has consistently been associated 
with reduced prevalence of TB disease.2
Key questions
What is already known?
 ► BCG is the only improved vaccine against tuberculo-
sis (TB). However, BCG vaccination is often delayed 
in low- income countries, and a major cause of delay 
in Guinea- Bissau is the restrictive vial- opening policy, 
where a vial of BCG is not opened unless 10–12 chil-
dren are present for vaccination at the same time.
 ► We identified one mathematical modelling study that 
estimated the global impact of different BCG coverage 
scenarios on TB mortality in children aged 0–14 years, 
which concluded that improving timeliness of BCG 
vaccination at birth was associated with reductions in 
TB deaths.
 ► We found no study estimating the health economic im-
pact of increasing timeliness, the impact of improving 
BCG timeliness on all- cause mortality, nor any studies 
assessing the impact at the country level.
What are the new findings?
 ► In this study, we provide the first country- level esti-
mates of the impact of change in BCG coverage and 
timeliness. We estimated that disregarding the restric-
tive vial- opening policy and vaccinating every child at 
the first contact with a health facility in Guinea- Bissau 
could reduce TB and all- cause mortality.
 ► Our study provides the first effect and cost- 
effectiveness estimates for this easily implementable 
intervention of disregarding the restrictive vial- opening 
policy, and our estimates show that it is both effec-
tive and cost- effective to disregard the restrictive vial- 
opening policy.
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TB is estimated to be among the top ten causes of 
death worldwide.3 In 2015, global paediatric all- cause 
mortality was estimated at 5.9 million deaths,4 and 
191 000 (95% CI: 132 000 to 257 000) of these were esti-
mated as attributable to TB.5 As paediatric TB is difficult 
to diagnose, prevention may be more feasible than cure, 
particularly in settings with high TB burden and few 
resources. Vaccination is part of the WHO strategy for 
reducing TB deaths by 95% between 2015 and 2035.1 6 
Recent estimates suggested that increasing global BCG 
coverage from 92% final coverage to an immediate 92% 
coverage at birth could reduce TB deaths <15 years by 
5449 per global birth cohort (95% uncertainty range 
(UR): 218–15 071).7
BCG may have beneficial non- specific effects (NSEs), 
protecting against disease unrelated to TB.8–11 In 2014, 
a WHO- commissioned review concluded that BCG may 
have beneficial NSEs reducing all- cause child mortality.12 
Thus, BCG delays may be important for both TB- specific 
mortality and all- cause mortality.
BCG is recommended at birth, and although global 
coverage is estimated at 88% by 12 months,13 this does 
not reveal underlying vaccination delays. To meet vaccine 
wastage targets, local practices of not opening a vial of 
BCG unless a sufficient number of children are present 
for vaccination have arisen (restrictive vial- opening 
policy) and BCG is consequently delayed in many low- 
income countries.14–16
The restrictive vial- opening policy is imposed with 
the goal of using scarce resources effectively. However, 
this saving may come at a cost and the impact has not 
been examined. The objective of this study was to esti-
mate the epidemiological impact and cost- effectiveness 
of disregarding the restrictive BCG vial- opening policy in 
Guinea- Bissau, considering both the TB- specific and all- 
cause mortality effects.
METHODS
We developed two static mathematical models, one for 
TB deaths based on a model developed by Roy et al7 and 
one for all- cause deaths, both in Microsoft Excel 2013 
(figure 1A,B). The model by Roy assumed all- or- nothing 
efficacy, where a proportion (corresponding to the 
vaccine efficacy) of BCG- vaccinated children are assumed 
to be fully protected, and the remainder are assumed to 
be unprotected. However, the mechanism of efficacy is 
unknown. As it is unrealistic to assume complete protec-
tion against all- cause mortality, we assumed leaky BCG 
vaccine efficacy in both models, that is, all BCG- vaccinated 
children are assumed partly protected corresponding to 
the vaccine efficacy (online supplemental appendix 3.1).
The primary outcomes were absolute and percentage 
change in TB deaths and all- cause deaths averted among 
children <5 years per birth cohort due to disregarding 
the restricted BCG vial- opening policy (vial- policy 
change). The current scenario with restrictive BCG vial- 
opening policy (baseline) was compared with the non- 
restrictive scenario, defined as a scenario in which every 
child was BCG vaccinated at the first registered health 
facility contact.
Data inputs and assumptions
Where data were available, we used country- specific 
estimates for Guinea- Bissau. Parameter values and data 
sources are summarised in table 1.
Population estimates
We used routine 2012–2017 surveillance data from the 
Bandim Health Project’s (BHP) urban and rural Health 
and Demographic Surveillance Systems (HDSS) to esti-
mate the daily individual risk of all- cause mortality and 
all- cause hospital admission in children aged 0–4 years 
(table 1, online supplemental appendix 1.2.1). We used 
WHO/UNICEF birth cohort estimates (online supple-
mental appendix 1.1) and World Bank estimate of 57 
years life- expectancy in Guinea- Bissau in 2017.17
TB data
For TB incidence and TB mortality, we used the 2016 
Guinea- Bissau Global Burden of Disease18 (GBD) esti-
mates, as reported TB data from Guinea- Bissau are likely 
underestimates. Using this information, we calculated a 
TB case fatality rate (CFR) of 0.21 (table 1). We assumed 
that all reported paediatric TB19 cases were hospitalised 
[personal communication: Victor Gomes, Programmatic 
Manager of MDR- TB, National TB Programme]. We 
calculated the proportion of hospitalised TB cases as 
reported cases divided by the GBD case estimate.
BCG coverage and timeliness
Using BHP routine data, we estimated BCG coverage 
and timeliness for the restrictive scenario using current 
estimates, and in the non- restrictive scenario using first 
health facility contact (figure 2, online supplemental 
appendix 1.2.2).
BCG vaccine efficacy
We used a BCG vaccine efficacy against TB death of 66% 
(95%CI: 8% to 88%).20 We assumed vaccine efficacy 
was constant regardless of age of administration.7 BCG 
protection may last for up to 15 years20, we, therefore, 
assumed no waning of protection between the ages 0 and 
4 years. As children rarely contribute to transmission,21 
Key questions
What do the new findings imply?
 ► Existing empirical evidence has demonstrated the importance of 
early BCG vaccination for TB control and that early BCG may reduce 
all- cause mortality. Our study strongly supports disregarding the re-
strictive vial- opening policy, as we find that this would reduce child 
mortality and be cost- effective.
 ► Since Guinea- Bissau is not the only setting with this restrictive vial- 
opening policy and delays in BCG vaccination, other settings are likely 
to also gain by disregarding the restrictive vial- opening policy.
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we assumed that a vial- policy change would not affect 
transmission.
We undertook a meta- analysis of seven studies from 
Guinea- Bissau (online supplemental appendix 1.2.3), 
and obtained a vaccine efficacy against all- cause death 
of 42% (95%CI:19% to 58%) (figure 3). For all- cause 
hospital admission, we used a vaccine- efficacy from a 
meta- analysis (3%, 95% CI:−31% to 28%).22 Vaccine effi-
cacies were assumed constant regardless of age at admin-
istration with no waning of protection before 5 years of 
age.
Costs
Costs were calculated using 2017 US dollar (US$) values. 
We included vaccination costs (including materials and 
freight), household costs of seeking BCG (US$ 1.92 
per child,23 online supplemental appendix 1.2.5), costs 
incurred by the health system per hospital bed day 
(US$ 15.58,24 online supplemental appendix 1.2.6), 
and time spent accompanying the child to the hospital 
(US$ 2.98 per hospital bed day,25 online supplemental 
appendix 1.2.6). Hospital admissions are free for chil-
dren <5 years in Guinea- Bissau,26 so we assumed no out- 
of- pocket payments for treatment. We assumed 50% 
vaccine wastage in the restrictive scenario, as a 20- dose 
vial is usually opened if 10 or more children are present. 
We assumed 95% wastage in the non- restrictive scenario, 
equivalent to vaccinating only one child per vial.
Mathematical model
TB deaths model
We developed a static cohort Markov model to calculate 
the absolute and relative difference in TB death between 
the restrictive and non- restrictive scenarios (online 
supplemental appendix 2.1). We estimated the daily risk 
of TB death in vaccinated and unvaccinated children 
in the restrictive scenario based on the total number of 
TB deaths (0–4 years), vaccine efficacy and the number 
of children BCG vaccinated and unvaccinated by age 
(table 1). To calculate the cumulative number of TB 
deaths per birth cohort in the first 5 years of life in 
each scenario, we applied the daily individual risk of TB 
among vaccinated children to the number of vaccinated 
children, and likewise for unvaccinated children. These 
risks were assumed constant between the ages 0 and 4 
years. The population at risk was adjusted for all- cause 
deaths by day; assuming BCG had no effect on all- cause 
mortality.
The number of TB cases per birth cohort in the first 
5 years of life in each scenario was estimated by dividing 
the number of TB deaths in each scenario by CFR of 
0.21 (table 1). To estimate TB hospital admissions, the 
proportion of TB cases identified through national TB 
surveillance was applied to the model- estimated number 
of TB cases in each scenario, assuming all identified TB 
cases were admitted.
Figure 1 (A) Structure of the TB model. White boxes indicate stages in the model. Grey boxes indicate the included costs. 
Full arrows indicate the model flow, while dashed lines indicate the flow in the real world. All children enter the model as 
BCG unvaccinated. Children are counted as BCG vaccinated from the registration of a BCG vaccine (restrictive scenario) or 
registration of first health facility contact (non- restrictive scenario). In each scenario, we estimated the number of TB deaths. 
Based on a case- fatality rate, we calculated the number of TB cases. Using national data on the number of identified TB cases, 
we assumed that all identified TB cases were admitted, we estimated the number of TB hospital admissions in each scenario. 
(B) Structure of the all- cause model. White boxes indicate stages in the model. Grey boxes indicate the included costs. Full 
arrows indicate the model flow, while dashed lines indicate the flow in the real world, but in the models, there were no direct 
link, as the numbers were derived and calculated separately, and we only used the data on admission to be able to include 
these in the cost analyses. All children enter the model as BCG unvaccinated. Children are counted as BCG vaccinated from 
the registration of a BCG vaccine (restrictive scenario) or registration of first health facility contact (non- restrictive scenario). In 
each scenario, we estimated the number of all- cause hospital admissions, and included cost of hospital admissions incurred 
by the healthcare system and household cost of hospital admission (time spent in the hospital). We estimated the number of 
all- cause deaths and calculated the cost- effectiveness of disregarding the restrictive vial- opening policy.
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All-cause deaths model
We developed a static cohort Markov model to calcu-
late the absolute and relative difference in all- cause 
death between the two scenarios (online supplemental 
appendix 2.2). We estimated daily, age- specific risk of 
all- cause death using the BHP routine all- cause mortality 
data (online supplemental appendix 1.2.1). Applying 
similar methods as the TB model, we used baseline data 
on BCG coverage by age, vaccine efficacy meta- estimate 
for all- cause death (online supplemental appendix 1.2.3), 
and the daily risk of all- cause death to calculate the daily 
risk of all- cause death in BCG- vaccinated children and in 
BCG- unvaccinated children, respectively.
We applied the estimated daily individual risk of all- 
cause mortality among BCG- vaccinated children to the 
number of BCG- vaccinated children, and likewise for 
unvaccinated children, and estimated daily and cumu-
lative all- cause deaths between 0 and 4 years under the 
restrictive and non- restrictive scenarios (online supple-
mental appendix 2.2). Using a similar approach, we 
calculated the absolute and relative difference in all- 
cause hospital admissions between scenarios (online 
supplemental appendix 2.3).
Increasing evidence suggests that vaccines may 
interact.12 27 We, therefore, conducted a secondary anal-
ysis to assess outcomes only in the period prior to receipt 
of other vaccines (0–6 weeks of age).
Cost-effectiveness analyses
Cost- effectiveness was assessed from a societal perspec-
tive, including total population- level vaccination costs, 
household costs of seeking BCG vaccination, and costs of 
hospital admission incurred by the health system and the 
household (online supplemental appendix 2.4).
We added the number of deaths per year between the 
ages 0 and 5 years in 1- year intervals, to calculate the 
total number of deaths averted. Life- years gained (LYG) 
in the non- restrictive scenario were calculated in each 
model by multiplying the number of TB deaths or all- 
cause deaths averted per year of life by the remaining 
life expectancy.17 As WHO recommends,28 we discounted 
future costs and life years by 3%/year. We calculated 
incremental cost- effectiveness ratios (ICERs) of a vial- 
policy change. We used Wood’s purchasing power parity 
adjusted cost- effectiveness threshold for Guinea- Bissau of 
US$22–US$645.29
Urban versus rural subanalyses
Vaccination opportunities, healthcare- seeking behav-
iour and number of children present at health centres 
are likely to differ between the urban and rural popu-
lation, resulting in different effects of a vial- policy 
change. We, therefore, calculated separate estimates 
for urban and rural Guinea- Bissau. We used the same 
approaches, but substituted risk of all- cause mortality, 
risk of all- cause hospital admission, BCG coverage, 
and birth cohort estimates with regional estimates.
Uncertainty and sensitivity analyses
We performed a probabilistic uncertainty anal-
ysis using Oracle Crystal Ball (Release 11.1.2.4.850, 
Oracle, USA), where a statistical distribution was set 
for each parameter with a reported UR (table 1). 
Location and scale parameters were estimated using 
the 2.5%, 50% and 97.5% percentiles in the ‘rriskDis-
tributions’ R package. Parameters with fixed values 
were not considered uncertain. A total of 100 000 
parameter sets and model outputs were generated 
through Monte- Carlo simulations. Median and 95% 
URs were calculated from the 100 000 model outputs.
In sensitivity analyses, we assessed the impact of 
assuming leaky BCG vaccine efficacy by adapting the 
TB model to all- or- nothing efficacy, as in previous 
Figure 2 BCG coverage estimates in Guinea- Bissau in the 
restrictive (baseline) scenario and when disregarding the 
restrictive BCG vial- opening policy.
Figure 3 Meta- analysis of the effect of BCG on all- cause 
mortality in Guinea- Bissau HRs below 1 indicate that BCG 
vaccine is associated with lower mortality. HRs above 1 
indicate that BCG vaccination is associated with higher 
mortality. 1: Kristensen et al9, 2: Aaby et al34, 3: Roth et 
al35, 4: Aaby et al36, 5: Biering- Sørensen et al37, 6: Biering- 
Sørensen et al8, 7: Thysen et al.38
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models7 30 (online supplemental appendix 2.5). 
We evaluated the impact of using GBD estimates 
of TB mortality in two sensitivity analyses, using 
WHO TB incidence31 combined with CFR estimates 
from Jenkins,32 and using modelled estimates of TB 
mortality from Dodd.5 We also varied the assumption 
of perfect correlation between (1) male and female 
TB estimates, and (2) agewise mortality estimates, to 
be uncorrelated in sensitivity analyses. We assumed 
very high wastage (95%) in the non- restrictive 
scenario, and therefore conducted sensitivity analyses 
with wastage assumptions in the restrictive scenario 
from 35% to 60% with 5% intervals, and in the non- 
restrictive scenario from 70% to 90%.
Patient and public involvement
The communities were involved in locating households 
for the HDSS data collection, when the BHP HDSS 
was setup. No participant was involved in setting the 
research question or the outcome measure, nor were 
they involved in developing the models, or design of 
the study. No participant was asked to advise on inter-
pretation or writing up the results. The results are 
disseminated to the national public health institute. 
There are no plans to disseminate the results of the 
research to study participants or the community.
RESULTS
Effects of a vial-policy change on TB-specific outcomes
Disregarding the restrictive vial opening policy was 
estimated to reduce TB deaths, admissions and cases 
by 11.0% (95% UR: 0.5%–28.8%). The number of TB 
deaths was 33 (UR: 13–89) per birth cohort in the 
restrictive scenario and 29 (UR: 11–79) in the non- 
restrictive scenario, averting 4 (UR: 0–15) TB deaths 
per birth cohort in the first 5 years of life. TB cases 
were reduced from 162 (UR: 96–273) to 142 (UR: 
82–245), and TB hospital admissions from 46 to 41 
(table 2).
Effects of a vial-policy change on all-cause outcomes
The vial- policy change was estimated to reduce all- cause 
mortality by 8.1% (UR: 3.3%–12.7%), from 4820 (UR: 
4309–5425) all- cause deaths in the restrictive scenario to 
4429 (UR: 3920–5028) all- cause deaths in the non- restrictive 

















Total no of paediatric TB 
deaths
33 (13 to 89) 29 (11 to 79) −4 (−15 to 0) −11.0% (−28.8% to −0.5%)
Total no of paediatric TB 
cases
162 (96 to 273) 142 (82 to 245) −18 (−54 to −1) −11.0% (−28.8% to −0.5%)
Total no of paediatric TB 
hospital admissions
46* 41 (33 to 46) −5 (−13 to 0) −11.0% (−28.8% to −0.5%)
Sub- analysis stratifying urban and rural regions
Total no of paediatric TB 
deaths—urban data
8 (3 to 22) 8 (3 to 21) 0 (−1 to 0) −2.6% (−8.3% to −0.1%)
Total no of paediatric TB 
deaths—rural data
26 (10 to 69) 21 (8 to 57) −4 (−17 to 0) −16.4% (−38.6% to −0.8%)
All- cause effects
Total no of all- cause deaths 4820 (4309 to 5425) 4429 (3920 to 5028) −392 (−624 to −158) −8.1% (−12.7% to −3.3%)
Total no of all- cause hospital 
admissions
5926 (5538 to 6346) 5940 (5532 to 6380) 18 (−125 to 133) 0.4% (−2.6% to 2.8%)
Subanalysis stratifying urban and rural regions
Total no of all- cause deaths 
urban data
1071 (897 to 1302) 961 (795 to 1180) −111 (−172 to -47) −10.4% (−15.3% to −4.5%)
Total no of all- cause deaths 
rural data
3787 (3303 to 4386) 3467 (2992 to 4048) −319 (−527 to −124) −8.4% (−13.5% to −3.3%)
*The number of paediatric TB hospital admissions is the reported number of TB cases from Guinea- Bissau in 2017 (Programa 
Nacional de Luta contra a Tuberculose. Relatório anualde tuberculose 2017: Ministério da Saúde Publica da Guiné-Bissau, 
2018).
TB, tuberculosis.
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scenario, averting 392 (UR: 158–624) all- cause deaths per 
birth cohort in the first 5 years of life (table 2). There was 
an estimated 0.4% (UR:−2.6 to 2.8%) increase in all- cause 
hospital admissions, due to more children surviving and 
becoming admitted to hospital (table 2).
Costs and cost-effectiveness of a vial-policy change
In both models, the vial- policy change resulted in higher 
BCG- vaccination costs and lower household costs. 
Accounting only for the TB- specific effects, the 95 (UR: 
4–397) discounted LYG resulted in an ICER of US$ 911 
(UR: 145–9142) per discounted LYG and US$ 26 527 
(UR :4225–2 66 291) per discounted TB death averted 
(table 3).
Including all- cause effects of BCG, the number of 
discounted LYG were 10 605 (UR: 4279–16,896), resulting 
in an ICER of US$9 (UR: 5–23) per discounted LYG and 
Table 3 Cost- effectiveness of disregarding the restrictive BCG vial- opening policy for the Guinea- Bissau birth cohort in 2017
Restrictive (baseline) scenario Non- restrictive scenario
No of children born in health facilities 33 354 33 354
No of children BCG- vaccinated at birth 13 438 33 354
No of children not BCG- vaccinated at birth 55 774 35 858
BCG coverage at 12 months of age 93 % 99 %
Total household costs of seeking BCG vaccination US$134 631 US$68 694
Total BCG vaccine costs US$26 221 US$279 769
Total injection supply costs US$3909 US$6640
TB- specific effects only Median (95% uncertainty range) Median (95% uncertainty range)
No of paediatric TB deaths 33 (13 to 89) 29 (11 to 79)
LYG by averted TB death – 195 (7 to 817)
LYG by averted TB death—discounted – 95 (4 to 397)
No of paediatric TB hospital admissions 46* 41 (33 to 46)
Costs of TB hospital admissions US$51 207 US$45 557
Costs of TB hospital admissions discounted US$47 011 US$41 813
Incremental costs of disregarding the restrictive vial- 
opening policy (including vaccination costs, household 
costs and costs averted by TB hospital admissions)
– US$184 692
Incremental costs of disregarding the restrictive vial- 
opening policy discounted
– US$185 144
ICER per LYG (USD) – 440 (69 to 4440)
ICER per LYG discounted (USD) – 911 (145 to 9142)
ICER per TB death averted (USD) – 24 269 (3827 to 2 44 869)
ICER per TB death averted discounted (USD) – 26 527 (4225 to 2 66 291)
All- cause effects Median (95% uncertainty range) Median (95% uncertainty range)
No of all- cause deaths 4820 (4309 to 5425) 4429 (3920 to 5028)
LYG by averted all- cause deaths – 22 166 (8949 to 35 288)
LYG by averted all- cause deaths—discounted – 10 605 (4279 to 16 896)
No of all- cause hospital admissions 5926 (5538 to 6346) 5940 (5532 to 6380)
Costs of all- cause hospital admissions US$549 815 US$551 478
Costs of all- cause hospital admissions discounted US$508 556 US$510 076
Incremental costs of disregarding the restrictive vial- 
opening policy (including vaccination costs, household 
costs and costs averted by hospital admissions)
– US$192 005
Incremental costs of disregarding the restrictive vial- 
opening policy discounted
– US$191 863
ICER per LYG (USD) – 4 (3 to 11)
ICER per LYG discounted (USD) – 9 (5 to 23)
ICER per all- cause death averted (USD) – 249 (144 to 615)
ICER per all- cause death averted discounted (USD) – 259 (150 to 639)
*The number of paediatric TB hospital admissions is the reported number of TB cases from Guinea- Bissau in 2017 (Programa Nacional de Luta 
contra a Tuberculose. Relatório anualde tuberculose 2017: Ministério da Saúde Publica da Guiné-Bissau, 2018).
ICER, incremental cost- effectiveness ratio; LYG, life- year gained; USD, US dollar 2017 value.
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US$259 (UR: 150–639) per discounted all- cause death 
averted (table 3).
Effects of a vial-policy change in urban and rural health 
regions
The vial- policy change in urban Guinea- Bissau was 
estimated to have a smaller effect on TB mortality, with 
2.6% (0.1%–8.3%) fewer TB deaths, corresponding 
to less than 1 TB death per birth cohort (table 2). 
There was, however, a larger impact in the all- cause 
model with 111 (UR: 47–172) fewer deaths and 10.4% 
(UR: 4.5%–15.3%) estimated lower mortality, as many 
children had vaccination opportunities within the 
first days of life, where all- cause mortality is highest. 
Including all- cause effects, the estimated ICERs were 
US$10 (UR: 6–23) per discounted LYG and US$280 
(UR: 173–653) per discounted all- cause death averted 
(online supplemental appendix 3.4).
In the rural population, the policy change was esti-
mated to reduce TB deaths by 16.4% (0.8%–38.6%), 
corresponding to 4 (UR: 0–17) fewer TB deaths. The 
resulting ICERs were US$524 (UR: 77–5455) per 
discounted LYG and US$15 272 (UR: 2245–159 037) 
per TB death averted. The estimated reduction in 
all- cause mortality was 8.4% (3.3%–13.5%) corre-
sponding to 319 (UR: 124–527) fewer all- cause deaths 
(table 4). The resulting ICERs were US$8 (UR: 4–20) 
per discounted LYG and US$221 (UR: 120–567) per 




Adapting the TB model structure from a model assuming 
leaky vaccine efficacy (main analysis) to all- or- nothing 
efficacy did not alter results (table 4). Similarly, assuming 
no correlations between mortality estimates yielded 
similar results (online supplemental appendix 3.5). The 
vial- policy change was cost saving in both TB and all- cause 
models when vaccine wastage was 80% or less in the non- 
restrictive scenario (online supplemental appendix 3.6).











Median (95% uncertainty 
range)
TB- specific effects
Total no of paediatric TB 
deaths - main analysis
33 (13 to 89) 29 (11 to 79) −4 (−15 to 0) −11.0% (−28.8% to −0.5%)
Sensitivity to BCG mode of action model structure
Total no of paediatric TB 
deaths—all- or- nothing 
BCG effectiveness
33 (13 to 89) 29 (11 to 79) −4 (−15 to 0) −11.0% (−28.8% to −0.5%)
Sensitivity to calibration data
Total no of paediatric 
TB deaths—WHO† and 
Jenkins‡ data
231 (196 to 272) 204 (156 to 252) −25 (−68 to −1) −11.0% (−28.8% to −0.5%)
Total no of paediatric TB 
deaths—P. Dodd§ data
238 (110 to 519) 209 (94 to 463) −25 (−94 to −1) −11.0% (−28.8% to −0.5%)
All- cause effects   
Total no of all- cause 
deaths day—main analysis 
day 0–1826
4820 (4309 to 5425) 4429 (3920 to 5028) −392 (−624 to −158) −8.1% (−12.7% to −3.3%)
Subanalysis limiting follow- up to scheduled age of next vaccination
Total no of all- cause 
deaths day 0–42
1922 (1612 to 2318) 1648 (1352 to 2028) −277 (−415 to −120) −14.5% (−20.7% to −6.3%)
Subanalysis excluding day 0
Total no of all- cause 
deaths day 1–1826
3838 (3417 to 4345) 3621 (3208 to 4112) −216 (−373 to −80) −5.6% (−9.5% to −2.1%)
*Percentage change comparing the non- restrictive scenario with the restrictive scenario.
†WHO.31
‡Jenkins HE et al32
§Dodd PJ et al5
TB, tuberculosis.
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Source of TB data
Both the WHO TB incidence31 combined with Jenkins 
CFR32 and the Dodd estimates5 resulted in 25 averted TB 
deaths per birth cohort in the first 5 years of life. However, 
UR were greater when using Dodd estimates (table 4).
Prior to other routine vaccines
Limiting the analyses to the period prior to other sched-
uled routine vaccines, the policy change was estimated to 




Disregarding the restrictive BCG vial- opening policy 
was estimated to reduce TB deaths by 11.0% (UR: 
0.5%–28.8%) corresponding to 4 (UR: 0–15) TB deaths 
averted per birth cohort. All- cause death estimates were 
reduced by 8.1% (UR: 3.3%–12.7%) corresponding to 
392 (UR: 158–624) all- cause deaths per birth cohort. 
The ICER of the vial- policy change was estimated as 
US$911 (UR: 145–9142) per discounted LYG by averting 
TB deaths. The estimated ICER considering all- cause 
mortality was considerably lower: US$9 (UR: 5–23) per 
discounted LYG. Compared with Wood’s purchasing 
power parity adjusted cost- effectiveness threshold for 
Guinea- Bissau (US$22–US$645),29 the most conservative 
wastage assumption (95% in the non- restrictive scenario) 
may not lead to the conclusion that the policy was cost 
effective assuming effect only on TB deaths. However, at 
less conservative wastage assumptions, the cost declined 
markedly and despite few TB deaths averted, changing 
the policy could be cost- effective for TB deaths, and the 
policy was highly cost- effective including the effect on all- 
cause deaths, demonstrating the potential importance of 
considering all- cause effects in vaccine cost- effectiveness 
evaluations. Importantly, in the non- restrictive scenario, 
increased costs were incurred by the health system, while 
household costs were reduced. Hence, the intervention 
is likely to increase equity.
The vial- policy change was associated with larger impact 
in rural than urban Guinea- Bissau, as vaccination delays 
are greater in rural Guinea- Bissau and mortality is higher.
Comparisons and perspectives
Previously, Roy estimated that increasing BCG coverage 
to 92% at birth globally could reduce TB deaths <15 years 
of age by 2.8%.7 We found a greater percentage reduction 
in TB deaths (11.0%, UR: 0.5%–28.8%) by improving 
timeliness of BCG vaccination. Greater delays in BCG 
vaccination in the restrictive scenario and more precise 
estimates of BCG coverage in Guinea- Bissau contribute 
to the difference.
In recent years, manufacturing problems have created 
BCG shortages, estimated to be associated with 7433 (UR: 
320–19 477) excess TB deaths in 0–14 year olds per global 
birth cohort,30 but potential excess all- cause deaths were 
not included. Our results suggest that if all- cause deaths 
had been estimated, the assessed public health impact 
of these shortages would have been substantially higher, 
and emphasise the importance of including all- cause 
mortality to inform the full impact of a policy change.
Strengths and limitations
We present the first model assessing impact and cost- 
effectiveness of the vial- opening policy change on all- 
cause mortality, and first country- level model assessing 
impact and cost- effectiveness of this change on any 
outcome. The BHP HDSS data allowed for country- 
representative age- specific estimates based on individual 
level data, which are more accurate than the aggregated 
data usually available. Results were robust to sensitivity 
analyses conducted.
Increasing vaccination coverage is usually resource 
demanding, but using the first registered health- facility 
contact to provide BCG could easily be implemented 
without additional initiatives. Thus, the high coverage in 
the non- restrictive scenario would be realistic if enough 
vaccines were available.
TB surveillance in Guinea- Bissau is limited and TB is 
likely underdiagnosed. Due to uncertainty in estimates of 
TB incidence and mortality, we assessed robustness of our 
results to the TB- calibration data by conducting sensitivity 
analyses using other data sources. The main estimates 
of absolute TB deaths averted were likely conservative, 
as using other data sources resulted in more TB deaths 
averted. The efficacy estimates of BCG against TB have 
varied between studies and populations,2 20 and thus the 
meta- analysed estimates have wide URs. We assumed that 
TB mortality was constant in 0–4 years old, since age- 
stratified data were not available. The estimates of TB 
cases and hospital admissions should be interpreted with 
caution as they are calculated based on different data 
sources assuming comparability.
The vaccine efficacy on all- cause deaths was estimated 
from trials in low- weight neonates and observational 
studies from Guinea- Bissau, which provided similar 
mortality estimates. More data from normal birth weight 
children would be of value. The current level of evidence 
is not sufficient to conclude on the duration of NSEs.
Cost estimates were derived from Guinea- Bissau. 
Household costs of seeking BCG vaccination23 and health 
system costs per hospital bed day were included.24 Out- of- 
pocket payments for treatment were not included, but as 
hospital admission for children is free, we expect out- of- 
pocket payments to be few. In main analyses, we conser-
vatively assumed only one child was vaccinated per vial 
in the non- restrictive scenario, therefore likely overesti-
mating the costs of the intervention, as more than one 
child would likely be vaccinated per vial. Sensitivity anal-
yses showed that the intervention would potentially be 
cost saving, if on average four children were vaccinated 
per vial. However, we did not calculate URs for sensitivity 
analyses on wastage assumptions, and this conclusion 
should therefore be interpreted with caution.
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Our models only included Guinea- Bissau. However, the 
restrictive vial- opening policy is not limited to Guinea- 
Bissau.15 33 While the exact impact and cost- effectiveness 
estimates are not directly transferable to other countries, 
the conclusions of the study are likely to be generalisable. 
Thus, important gains are likely to be possible in other 
settings with a similar practice.
CONCLUSION
Disregarding the restrictive vial- opening policy in Guinea- 
Bissau was estimated to result in small reductions in TB 
deaths and substantial reductions in all- cause deaths. Our 
results support that it would be cost- effective to disregard 
the restrictive vial- opening policy.
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